Immatics (IMTX) Retained Earnings (2019 - 2026)
Immatics (IMTX) posted Retained Earnings of -$10.0 million for Q4 2025, down 5.53% sequentially from -$9.5 million in Q3 2025, and down 1007.8% YoY from $1.1 million in Q4 2024.
Analysis
Immatics (IMTX) Retained Earnings (2019 - 2026) Analysis & Trends
Immatics has reported Retained Earnings for 7 years, with the latest figure at -$10.0 million in Q4 2025.
- Quarterly Retained Earnings fell 1007.8% year-over-year to -$10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.0 million (down 1007.8% YoY) and the FY2025 annual result came in at -$9.7 million, down 969.92% from the prior year.
- Retained Earnings slipped to -$10.0 million in Q4 2025 per IMTX's latest filing, from -$9.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $1.1 million in Q4 2024 and troughed at -$692.2 million in Q3 2024.
- A 5-year average of -$161.1 million and a median of -$5.7 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 162.59% in 2024, down 89207.76% in 2024.
- Over 5 years, Retained Earnings stood at -$615.2 million in 2021, then advanced by 15.41% to -$520.4 million in 2022, then jumped by 99.66% to -$1.8 million in 2023, then jumped by 162.59% to $1.1 million in 2024, then plunged by 1007.8% to -$10.0 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$10.0 million, -$9.5 million, and -$8.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.10 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -4.00 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.05 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 4.38 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -1.05 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.05 Bn |
| Mar 31, 2026 | -987.88 Mn |
| Dec 31, 2025 | -914.92 Mn |
| Sep 30, 2025 | -877.13 Mn |
| Jun 30, 2025 | -792.08 Mn |
| Mar 31, 2025 | -662.05 Mn |
| Dec 31, 2024 | -629.98 Mn |
| Sep 30, 2024 | -692.20 Mn |
| Jun 30, 2024 | -673.05 Mn |
| Mar 31, 2024 | -659.42 Mn |
| Dec 31, 2023 | -650.68 Mn |
| Sep 30, 2023 | -621.74 Mn |
| Jun 30, 2023 | -593.09 Mn |
| Mar 31, 2023 | -558.19 Mn |
| Dec 31, 2022 | -520.44 Mn |
| Sep 30, 2022 | -491.10 Mn |
| Jun 30, 2022 | -497.39 Mn |
| Mar 31, 2022 | -507.47 Mn |
| Dec 31, 2021 | -615.24 Mn |
| Sep 30, 2021 | -614.44 Mn |